Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram

Neuropeptides appear to play a role in the pathophysiology of depression and electroconvulsive treatment and lithium affect these compounds in human cerebrospinal fluid (CSF) and rodent brain. Consequently, we investigated whether long-term treatment with the selective serotonin reuptake inhibitor (...

Full description

Saved in:
Bibliographic Details
Published in:The international journal of neuropsychopharmacology 2005-09, Vol.8 (3), p.403-410
Main Authors: Nikisch, Georg, Ågren, Hans, Eap, Chin B., Czernik, Adelheid, Baumann, Pierre, Mathé, Aleksander A.
Format: Article
Language:English
Subjects:
Adult
Analysis of Variance
Antidepressive Agents, Second-Generation - therapeutic use
Citalopram - therapeutic use
Corticotropin-Releasing Hormone - blood
Corticotropin-Releasing Hormone - cerebrospinal fluid
Depression - blood
Depression - cerebrospinal fluid
Depression - drug therapy
Female
Humans
Immunoassay - methods
Male
Medicin och hälsovetenskap
Middle Aged
Neuropeptide Y - blood
Neuropeptide Y - cerebrospinal fluid
Time Factors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Neuropeptides appear to play a role in the pathophysiology of depression and electroconvulsive treatment and lithium affect these compounds in human cerebrospinal fluid (CSF) and rodent brain. Consequently, we investigated whether long-term treatment with the selective serotonin reuptake inhibitor (SSRI) citalopram (Cit) would also affect neuropeptides in CSF of depressed patients. Changes in CSF monoamine metabolites were also explored. CSF concentrations of corticotropin-releasing hormone (CRH)-like immunoreactivity (-LI), neuropeptide Y (NPY)-LI, and Cit were determined in 21 patients with major depression. Lumbar puncture was performed in the morning at baseline and was repeated after at least 4 wk of Cit treatment (40 mg/d). The severity of depression was assessed by the Hamilton Rating Scale for Depression (HAMD). Cit treatment was associated with a significant increase in NPY-LI and decrease in CRH-LI. An evaluation of the relationship between changes in concentrations of NPY-LI, CRH-LI, and the clinical response showed significant correlations between these parameters. Significant NPY and CRH changes in CSF following treatment as well as correlations to changes in HAMD support the hypothesis that these two peptides play a role in affective disorders and are markers of therapeutic response.
ISSN:1461-1457
1469-5111
DOI:10.1017/S1461145705005158